AbbVie

AbbVie

Yahoo Finance • 2 hours ago

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Conexeu Sciences Inc. Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12-... Full story

Yahoo Finance • 2 hours ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

SkinMedica® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation Debuts flagship retail experi... Full story

Yahoo Finance • 5 hours ago

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Drug pricing has been hanging over the pharmaceutical industry for years, and the Trump administration didn't eliminate that pressure. It did, however, pursue voluntary pricing agreements with many of the industry's largest drugmakers. Sin... Full story

Yahoo Finance • 21 hours ago

3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors

I love technology stocks -- even before the artificial intelligence boom, I was a big fan of Alphabet, Microsoft, Nvidia, and the rest of the tech world. But what I don't love about them is their stingy (or nonexistent) dividend payouts.... Full story

Yahoo Finance • yesterday

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Quick Read JNJ has beaten earnings four consecutive quarters, with Q1 revenue jumping 10% to $24 billion and full-year guidance raised above $100 billion. JNJ's nearly $9 billion MedTech segment growing at 8% gives it diversification that... Full story

Yahoo Finance • 3 days ago

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Key Points State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech indus... Full story

Yahoo Finance • 3 days ago

Which is the Better Choice for Healthcare Investors? IYH or BBH?

Investors choosing between iShares U.S. Healthcare ETF (NYSEMKT:IYH) and VanEck Biotech ETF (NASDAQ:BBH) may weigh the broader, lower-volatility healthcare exposure of IYH against the concentrated, high-growth biotechnology focus of BBH.... Full story

Yahoo Finance • 4 days ago

Amazon, Microsoft and Meta Among HSBC Earnings Picks

This article first appeared on GuruFocus. HSBC identified 10 Buy-rated stocks it believes are well positioned ahead of the second-quarter earnings season, citing favorable trends across technology, financial, consumer and industrial secto... Full story

Yahoo Finance • 4 days ago

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. West Pharmaceutical Services (NYSE:WST) has sold the rights and facilities related to its SmartDos... Full story

Yahoo Finance • 4 days ago

Catalyst Watch: Bank earnings, Netflix results, Alzheimer's conference

[NETFLIX corporate office building with signage on top, located at 1341 Vine Street, Los Angeles] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events... Full story

Yahoo Finance • 4 days ago

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

Quick Read JNJ notched its 64th consecutive dividend hike and raised full-year guidance, while AbbVie's 12% revenue growth was clouded by a $744 million pipeline charge. Skyrizi and Rinvoq grew 31% and 23% respectively, already offsetting... Full story

Yahoo Finance • 5 days ago

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

Key Points Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Invesco Pharmaceuticals ETF Inv... Full story

Yahoo Finance • 5 days ago

Cystic Fibrosis Market, Global & Regional Now Available; Profiles Vertex Pharmaceuticals, AbbVie, and Other Frontrunner Competitors in Orphan Drug Markets

Company Logo The cystic fibrosis market is expanding due to rising disease prevalence and advancements in targeted therapies and precision medicine. Predominantly affecting Western populations, over 30,000 people in the U.S. live with thi... Full story

Yahoo Finance • 5 days ago

Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight

Companies like Biogen and Royalty Pharma (Litifilimab), Biogen and UCB(Dapirolizumab pegol), Idorsia Pharmaceuticals and Viatris (Cenerimod), Novartis (Ianalumab, YTB3231), Kyowa Kirin (KK-4277), and others are advancing late, mid, and ear... Full story

Yahoo Finance • 5 days ago

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

VanEck Pharmaceutical ETF (NASDAQ:PPH) offers concentrated exposure to global drugmakers, while Vanguard Health Care ETF (NYSEMKT:VHT) provides a much broader, lower-cost entry point into the diverse healthcare landscape. Both funds targe... Full story

Yahoo Finance • 6 days ago

Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 days ago

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 days ago

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list. TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju incre... Full story

Yahoo Finance • 7 days ago

Is AbbVie (ABBV) Fully Valued After Its Tepkinly Approval?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AbbVie (ABBV) is back in focus after the European Commission grant... Full story

Yahoo Finance • 7 days ago

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

Maximizing dividend income isn't all about chasing high yields. A company must have a healthy, growing business to generate the profits needed to pay dividends and raise them over time. A high dividend yield can even be a red flag, a trap... Full story